Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 7/20 | 0.45 |
| ▸ | PNP | P00491 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 2/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | KRAS | P01116 | 7/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1344477 | 0.89 | HINT1 (0.40) | HINT1PNPGSK3ARPS6KA3MAPK14 | |
| SCHEMBL5216686 | 0.89 | HINT1 (0.46) | HINT1PNPGSK3ARPS6KA3MAPK14 | |
| SCHEMBL25688968 | 0.84 | KDM4E (0.44) | HINT1TAS1R3TAS1R1HPGD | |
| SCHEMBL5668128 | 0.83 | KDM4E (0.48) | HINT1TAS1R3TAS1R1HPGD | |
| SCHEMBL12991055 | 0.82 | HINT1 (0.33) | HINT1TAS1R3TAS1R1HPGD | |
| SCHEMBL6243042 | 0.82 | HINT1 (0.50) | HINT1PNPGSK3ARPS6KA3MAPK14 | |
| SCHEMBL18510883 | 0.81 | KDM4E (0.44) | HINT1TAS1R3TAS1R1HPGD | |
| SCHEMBL18510954 | 0.81 | KDM4E (0.44) | HINT1TAS1R3TAS1R1HPGD | |
| SCHEMBL14896399 | 0.81 | HINT1 (0.49) | HINT1PNPGSK3ARPS6KA3MAPK14 | |
| SCHEMBL18521378 | 0.81 | KDM4E (0.48) | HINT1TAS1R3TAS1R1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2899278-A1 | iRNA agents targeting VEGF | Alnylam Pharmaceuticals Inc. (US) | 2015-07-29 | — | — | EP | disclosed |
| EP-2636739-B1 | iRNA agents targeting VEGF | ALNYLAM PHARMACEUTICALS INC (US) | 2014-12-10 | — | — | EP | disclosed |
| EP-2636739-A1 | iRNA agents targeting VEGF | Alnylam Pharmaceuticals Inc. (US) | 2013-09-11 | — | — | EP | disclosed |
| EP-2365077-B1 | iRNA agents targeting VEGF | ALNYLAM PHARMACEUTICALS INC (US) | 2013-05-08 | — | — | EP | disclosed |
| EP-2365077-A1 | iRNA agents targeting VEGF | Alnylam Pharmaceuticals, Inc. (US) | 2011-09-14 | — | — | EP | disclosed |